{"filing":{"accession_number":"0001628280-26-058605","cik":"0001516551","ticker":"SKYE","company_name":"Skye Bioscience, Inc.","form":"8-K","filing_date":"2026-08-24","report_date":"2026-08-21","primary_document":"skye-20260821.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026058605/skye-20260821.htm"},"events":[{"id":29138,"run_id":26664,"accession_number":"0001628280-26-058605","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.93,"summary":"Skye Bioscience entered into a Securities Purchase Agreement with Redmile Biopharma Investments III, L.P. on August 21, 2026, to sell up to $22,000,000 of ELOC Shares (common and non-voting convertible shares) plus a warrant to purchase additional shares valued at $5,000,000, pursuant to Section 4(a)(2) exemption. The transaction includes a 19.99% cap on outstanding shares (subject to stockholder approval for excess) and a 9.99% beneficial ownership limitation for the investor, representing significant equity dilution for existing shareholders.","company_name":"Skye Bioscience, Inc.","ticker":"SKYE","filing_date":"2026-08-24","form":"8-K","submitted_at":null,"items":[{"id":31311,"accession_number":"0001628280-26-058605","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Company entered into a Securities Purchase Agreement with Redmile Biopharma Investments III, L.P. on August 21, 2026, to sell up to $22,000,000 of ELOC Shares (common and non-voting convertible shares) plus a warrant to purchase additional shares valued at $5,000,000. This is a dilutive equity issuance with a 19.99% cap on outstanding shares (subject to stockholder approval for excess) and a 9.99% beneficial ownership limitation for the investor. The transaction is material to investors as it represents significant equity dilution and is part of a broader financing package alongside a PIPE transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T20:03:16.480503+00:00","company_name":"","ticker":null,"filing_date":""},{"id":31312,"accession_number":"0001628280-26-058605","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses unregistered issuance of equity securities (ELOC Shares, ELOC Conversion Shares, Warrant Shares) pursuant to Section 4(a)(2) exemption. This is a classic dilutive private placement that would materially affect shareholder ownership and capital structure, particularly relevant for a small-cap bioscience company raising capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T20:03:16.480503+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31311,"accession_number":"0001628280-26-058605","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Company entered into a Securities Purchase Agreement with Redmile Biopharma Investments III, L.P. on August 21, 2026, to sell up to $22,000,000 of ELOC Shares (common and non-voting convertible shares) plus a warrant to purchase additional shares valued at $5,000,000. This is a dilutive equity issuance with a 19.99% cap on outstanding shares (subject to stockholder approval for excess) and a 9.99% beneficial ownership limitation for the investor. The transaction is material to investors as it represents significant equity dilution and is part of a broader financing package alongside a PIPE transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T20:03:16.480503+00:00","company_name":"Skye Bioscience, Inc.","ticker":"SKYE","filing_date":"2026-08-24"},{"id":31312,"accession_number":"0001628280-26-058605","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses unregistered issuance of equity securities (ELOC Shares, ELOC Conversion Shares, Warrant Shares) pursuant to Section 4(a)(2) exemption. This is a classic dilutive private placement that would materially affect shareholder ownership and capital structure, particularly relevant for a small-cap bioscience company raising capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T20:03:16.480503+00:00","company_name":"Skye Bioscience, Inc.","ticker":"SKYE","filing_date":"2026-08-24"}]}